Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Lantheus Holdings (NQ: LNTH )

72.46 -2.19 (-2.93%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 4, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Lantheus Holdings

< Previous 1 2 Next >
Lantheus Announces Top Rated Oral Presentation Featuring PYLARIFY AI™ at the 2023 European Association of Nuclear Medicine (EANM) Annual Meeting
From Lantheus Holdings, Inc.
Via GlobeNewswire
Lantheus to Present at the Wells Fargo Healthcare Conference
From Lantheus Holdings, Inc.
Via GlobeNewswire
Lantheus Announces Agreement to Sell RELISTOR® Royalties to HealthCare Royalty
Agreement enhances Lantheus’ strong liquidity position and supports continued pipeline advancement and commercial readiness 
From Lantheus Holdings, Inc.
Via GlobeNewswire
Lantheus Reports Second Quarter 2023 Financial Results
From Lantheus Holdings, Inc.
Via GlobeNewswire
Lantheus to Host Second Quarter 2023 Earnings Conference Call and Webcast on August 3, 2023, at 8:00 a.m. Eastern Time
From Lantheus Holdings, Inc.
Via GlobeNewswire
Lantheus Announces Presentations Featuring PYLARIFY AI™ at the 2023 Society for Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting
From Lantheus Holdings, Inc.
Via GlobeNewswire
Lantheus to Present at the Jefferies Healthcare Conference
From Lantheus Holdings, Inc.
Via GlobeNewswire
Lantheus Announces Payment to Contingent Value Rights (CVR) Holders of $99.7 million or $1.15 per CVR
PYLARIFY success leads to maximum payment in first year 
From Lantheus Holdings, Inc.
Via GlobeNewswire
Lantheus Reports First Quarter 2023 Financial Results
From Lantheus Holdings, Inc.
Via GlobeNewswire
Lantheus and POINT Biopharma Announce FDA Grants Fast Track Designation for ¹⁷⁷Lu-PNT2002 for the Treatment of Metastatic Castration Resistant Prostate Cancer
From Lantheus Holdings, Inc.; POINT Biopharma Global Inc.
Via GlobeNewswire
Lantheus to Host First Quarter 2023 Earnings Conference Call and Webcast on May 4, 2023, at 8:00 a.m. Eastern Time
From Lantheus Holdings, Inc.
Via GlobeNewswire
Lantheus Announces Two Key Executive Promotions
Paul Blanchfield promoted to President; Dan Niedzwiecki promoted to Chief Administrative Officer 
From Lantheus Holdings, Inc.
Via GlobeNewswire
Are These Medical Device Makers Getting Ready To Rally?
Current trends and changing demographics are behind growth of medical technology companies. An aging population and a shift to in-home care are among factors. 
Via MarketBeat
Lantheus Reports Fourth Quarter and Full Year 2022 Financial Results
From Lantheus Holdings, Inc.
Via GlobeNewswire
Lantheus Presents Data Reinforcing Real-World Clinical Utility of Piflufolastat F 18 PET Scanning in Men with Recurrent Prostate Cancer and Low PSA Levels
Data presented at the American Society of Clinical Oncology Genitourinary Cancers Symposium Demonstrate Potential Benefits of Piflufolastat F 18 Decision Making on Treatment Plans 
From Lantheus Holdings, Inc.
Via GlobeNewswire
Lantheus to Host Fourth Quarter and Full Year 2022 Earnings Conference Call and Webcast on February 23, 2023, at 8:00 a.m. Eastern Time
From Lantheus Holdings, Inc.
Via GlobeNewswire
Lantheus to Present Piflufolastat F 18 Data at the 2023 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium
From Lantheus Holdings, Inc.
Via GlobeNewswire
Lantheus Announces Acquisition of Cerveau Technologies, Inc., Expanding Imaging Pipeline into Alzheimer’s Disease
MK-6240 is an F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer’s Disease 
From Lantheus Holdings, Inc.
Via GlobeNewswire
Lantheus to Present at the J.P. Morgan 2023 Healthcare Conference
From Lantheus Holdings, Inc.
Via GlobeNewswire
Lantheus Announces Closing of Strategic Collaboration and Exclusive License Agreements for the Commercialization of PNT2002 & PNT2003 with POINT Biopharma
From Lantheus Holdings, Inc.
Via GlobeNewswire
Lantheus Grants Rights for the Use of its Microbubbles to SonoThera for its Ultrasound-Guided Nonviral Gene Therapy Platform
From Lantheus Holdings, Inc.
Via GlobeNewswire
Lantheus Holdings, Inc. Announces Pricing of Offering of $500 Million Convertible Senior Notes due 2027
From Lantheus Holdings, Inc.
Via GlobeNewswire
Lantheus Holdings, Inc. Announces Proposed Offering of $500 Million Convertible Senior Notes due 2027
From Lantheus Holdings, Inc.
Via GlobeNewswire
Lantheus Announces Appointment of Amanda Morgan as Senior Vice President, Commercial
From Lantheus Holdings, Inc.
Via GlobeNewswire
Lantheus Announces the Approval of DEFINITY® (Perflutren Lipid Microsphere) by China’s NMPA
DEFINITY is the leading diagnostic ultrasound enhancing agent for patients with suboptimal echocardiograms 
From Lantheus Holdings, Inc.
Via GlobeNewswire
Lantheus and POINT Biopharma Announce Strategic Collaboration and Exclusive License Agreements for the Commercialization of PNT2002 & PNT2003
From Lantheus Holdings, Inc.
Via GlobeNewswire
S&P 500 Component DexCom Set For Further Price, Earnings Growth
Glucose monitor maker DexCom surged 19% after its Q3 report, and shares are holding those gains. Wall Street sees more growth ahead in 2023. 
Via MarketBeat
Topics Stocks
Exposures US Equities
Lantheus to Present at the Jefferies London Healthcare Conference
From Lantheus Holdings, Inc.
Via GlobeNewswire
Lantheus Reports Third Quarter 2022 Financial Results
From Lantheus Holdings, Inc.
Via GlobeNewswire
MarketBeat: Week in Review 10/24-10/28
Stocks finished the week on a bullish note, and the MarketBeat analysts continue to guide you to the stocks and stories that are moving the market 
Via MarketBeat
Topics Economy Electric Vehicles
Exposures Economy Electric Vehicles Interest Rates
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.